|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 148.00 GBX | +1.37% |
|
+3.86% | +15.62% |
| Jun. 02 | Diaceutics PLC, 2025 Earnings Call, May 26, 2026 | |
| May. 26 | Diaceutics PLC Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
Company Valuation: Diaceutics PLC
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 85.75 | 63.68 | 73.32 | 106.1 | 108.7 | 125.3 | - | - |
| Change | - | -25.74% | 15.14% | 44.67% | 2.47% | 15.3% | - | - |
| Enterprise Value (EV) 1 | 66.08 | 43.84 | 56.65 | 93.32 | 101.3 | 117.6 | 113.2 | 106.4 |
| Change | - | -33.66% | 29.24% | 64.73% | 8.6% | 16.04% | -3.76% | -5.98% |
| P/E | - | 89.9x | -42x | -62.1x | - | - | - | - |
| PBR | - | 1.53x | 1.8x | 2.66x | 2.67x | 3.05x | 2.72x | 2.25x |
| PEG | - | - | 0x | 25.71x | - | - | - | - |
| Capitalization / Revenue | 6.15x | 3.26x | 3.09x | 3.3x | 2.83x | 2.67x | 2.23x | 1.87x |
| EV / Revenue | 4.74x | 2.25x | 2.39x | 2.9x | 2.64x | 2.5x | 2.01x | 1.59x |
| EV / EBITDA | 28.1x | 12.2x | 24x | 22.2x | 13.4x | 11.4x | 8.22x | 5.86x |
| EV / EBIT | 120x | 76.4x | -18.8x | -38x | 57.5x | 36.8x | 22x | 11.3x |
| EV / FCF | -13.1x | 194x | -16x | -23.4x | -19.2x | 237x | 16.5x | 11x |
| FCF Yield | -7.61% | 0.52% | -6.26% | -4.27% | -5.2% | 0.42% | 6.04% | 9.08% |
| Dividend per Share 2 | - | - | - | - | - | - | - | 1 |
| Rate of return | - | - | - | - | - | - | - | 67.6% |
| EPS 2 | - | 0.0084 | -0.0207 | -0.0202 | - | - | - | - |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 13.94 | 19.5 | 23.7 | 32.16 | 38.44 | 47 | 56.31 | 67.06 |
| EBITDA 1 | 2.349 | 3.583 | 2.357 | 4.206 | 7.573 | 10.35 | 13.77 | 18.16 |
| EBIT 1 | 0.55 | 0.574 | -3.018 | -2.455 | 1.761 | 3.2 | 5.149 | 9.381 |
| Net income 1 | 0.561 | 0.724 | -1.746 | -1.703 | 0.097 | -1.1 | 1.5 | 4.3 |
| Net Debt 1 | -19.68 | -19.84 | -16.67 | -12.74 | -7.344 | -7.71 | -12.14 | -18.9 |
| Reference price 2 | 1.020 | 0.755 | 0.870 | 1.255 | 1.280 | 1.480 | 1.480 | 1.480 |
| Nbr of stocks (in thousands) | 84,069 | 84,339 | 84,274 | 84,515 | 84,912 | 84,670 | - | - |
| Announcement Date | 3/22/22 | 4/17/23 | 5/21/24 | 5/13/25 | 5/26/26 | - | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 2.5x | 11.36x | -.--% | 166M | |
| -176.61x | 25.86x | 62.11x | -.--% | 73.41B | |
| 38.97x | 2.98x | 23.62x | 1.13% | 4.35B | |
| 106.01x | 13.64x | 19.62x | 0.28% | 3.44B | |
| -26.18x | - | - | 0.1% | 1.29B | |
| 42.51x | 17.55x | 27.23x | 0.54% | 1.24B | |
| 15.55x | - | - | 0.37% | 1.17B | |
| 24.06x | 3.78x | 13.58x | 0.68% | 1.1B | |
| Average | 3.47x | 11.05x | 26.25x | 0.39% | 10.77B | |
| Weighted average by Cap. | -143.81x | 23.71x | 57.11x | 0.09% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- DXRX Stock
- Valuation Diaceutics PLC
Select your edition
All financial news and data tailored to specific country editions
